{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:32:45Z","timestamp":1773077565885,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T00:00:00Z","timestamp":1271721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/nrendo.2010.49","type":"journal-article","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T10:08:54Z","timestamp":1271758134000},"page":"326-334","source":"Crossref","is-referenced-by-count":45,"title":["Adjunct therapy for type 1 diabetes mellitus"],"prefix":"10.1038","volume":"6","author":[{"given":"Harold E.","family":"Lebovitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"BFnrendo201049_CR1","doi-asserted-by":"crossref","unstructured":"[No authors listed] Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 18, 1415\u20131427 (1995).","DOI":"10.2337\/diacare.18.11.1415"},{"key":"BFnrendo201049_CR2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2337\/dc06-2053","volume":"30","author":"G Pambianco","year":"2007","unstructured":"Pambianco, G., Costacou, T. & Orchard, T. J. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30, 1248\u20131254 (2007).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdiacomp.2006.10.005","volume":"22","author":"M McGill","year":"2008","unstructured":"McGill, M., Molyneaux, L., Twigg, S. M. & Yue, D. K. The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J. Diabetes Complications 22, 18\u201323 (2008).","journal-title":"J. Diabetes Complications"},{"key":"BFnrendo201049_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2337\/dc08-2022","volume":"32","author":"LM Thorn","year":"2009","unstructured":"Thorn, L. M. et al. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32, 950\u2013952 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR5","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2337\/diab.41.9.1042","volume":"41","author":"PI Shishko","year":"1992","unstructured":"Shishko, P. I., Kovalev, P. A., Goncharov, V. G. & Zajarny, I. U. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes 41, 1042\u20131049 (1992).","journal-title":"Diabetes"},{"key":"BFnrendo201049_CR6","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1210\/jc.2007-2350","volume":"93","author":"J Frystyk","year":"2008","unstructured":"Frystyk, J. et al. Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone\/insulin-like growth factor-1 axis. J. Clin. Endocrinol. Metab. 93, 1758\u20131766 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201049_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1001\/jama.280.2.140","volume":"280","author":"JQ Purnell","year":"1998","unstructured":"Purnell, J. Q. et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from DCCT. JAMA 280, 140\u2013146 (1998).","journal-title":"JAMA"},{"key":"BFnrendo201049_CR8","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2337\/diacare.28.8.2019","volume":"28","author":"LM Thorn","year":"2005","unstructured":"Thorn, L. M. et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28, 2019\u20132024 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2006-0007","volume":"28","author":"J Gromada","year":"2007","unstructured":"Gromada, J., Franklin, I. & Wolheim, C. B. \u03b1-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28, 84\u2013116 (2007).","journal-title":"Endocr. Rev."},{"key":"BFnrendo201049_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1210\/er.2006-0026","volume":"28","author":"BE Dunning","year":"2007","unstructured":"Dunning, B. E. & Gerich, J. E. The role of \u03b1-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr. Rev. 28, 253\u2013283 (2007).","journal-title":"Endocr. Rev."},{"key":"BFnrendo201049_CR11","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2337\/dc09-0798","volume":"32","author":"BA Cooperberg","year":"2009","unstructured":"Cooperberg, B. A. & Cryer, P. E. Beta-cell mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 32, 2275\u20132280 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1677\/JOE-08-0290","volume":"199","author":"I Quesada","year":"2008","unstructured":"Quesada, I., Tudur\u00ed, E., Ripoll, C. & Nadal A. Physiology of the pancreatic \u03b1-cell and glucagon secretion: role in glucose homeostasis and diabetes. J. Endocrinol. 199, 5\u201319 (2008).","journal-title":"J. Endocrinol."},{"key":"BFnrendo201049_CR13","doi-asserted-by":"publisher","first-page":"R1792","DOI":"10.1152\/ajpregu.00777.2006","volume":"292","author":"SF Andrew","year":"2007","unstructured":"Andrew, S. F., Dinh, T. T. & Ritter, S. Localized glucoprivation of hindbrain elicits corticosterone and glucagon secretion. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R1792\u2013R1798 (2007).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"Suppl. 1","key":"BFnrendo201049_CR14","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/ijo.2009.10","volume":"33","author":"HJ Grill","year":"2009","unstructured":"Grill, H. J. & Hayes, M. R. The nucleus tractus solitarius: a portal for visceral afferent signals processing, energy status assessment and integration of their combined effects on food intake. Int. J. Obes. (Lond.) 33 (Suppl. 1), S11\u2013S15 (2009).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"BFnrendo201049_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2337\/dc08-0575","volume":"31","author":"RJ Brown","year":"2008","unstructured":"Brown, R. J., Sinaii, N. & Rother, K. I. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31, 1403\u20131404 (2008).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR16","first-page":"E283","volume":"277","author":"P Shah","year":"1999","unstructured":"Shah, P., Basu, A., Basu, R. & Rizza, R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am. J. Physiol. 277, E283\u2013E290 (1999).","journal-title":"Am. J. Physiol."},{"key":"BFnrendo201049_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/BF00400362","volume":"36","author":"M Horowitz","year":"1993","unstructured":"Horowitz, M., Edelbroek, M. A., Wishart, J. M. & Straathof, J. W. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36, 857\u2013862 (1993).","journal-title":"Diabetologia"},{"key":"BFnrendo201049_CR18","first-page":"2220","volume":"36","author":"KL Jones","year":"1995","unstructured":"Jones, K. L. et al. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J. Nucl. Med. 36, 2220\u20132228 (1995).","journal-title":"J. Nucl. Med."},{"key":"BFnrendo201049_CR19","doi-asserted-by":"publisher","first-page":"E103","DOI":"10.1152\/ajpendo.00514.2007","volume":"294","author":"HJ Woerle","year":"2008","unstructured":"Woerle, H. J. et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am. J. Physiol. Endocrinol. Metab. 294, E103\u2013E109 (2008).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrendo201049_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/0016-5085(88)90248-X","volume":"94","author":"JL Barnett","year":"1988","unstructured":"Barnett, J. L. & Owyang, C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 94, 739\u2013744 (1988).","journal-title":"Gastroenterology"},{"key":"BFnrendo201049_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/BF00400569","volume":"30","author":"RJ Fraser","year":"1990","unstructured":"Fraser, R. J. et al. Hyperglycemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30, 675\u2013680 (1990).","journal-title":"Diabetologia"},{"key":"BFnrendo201049_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1464-5491.1993.tb00141.x","volume":"10","author":"E Schwarcz","year":"1993","unstructured":"Schwarcz, E., Palm\u00e9r, M., Aman, J., Lindkvist, B. & Beckman, K.-W. Hypoglycemia increases gastric emptying rate in patients with type 1 diabetes mellitus. Diabet. Med. 10, 660\u2013663 (1993).","journal-title":"Diabet. Med."},{"key":"BFnrendo201049_CR23","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2337\/dc07-2446","volume":"31","author":"HJ Woerle","year":"2008","unstructured":"Woerle, H. J. et al. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care 31, 2325\u20132331 (2008).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1054-3589(05)52018-0","volume":"52","author":"A Young","year":"2005","unstructured":"Young, A. Amylin physiology and pharmacology: clinical studies. Adv. Pharmacol. 52, 289\u2013320 (2005).","journal-title":"Adv. Pharmacol."},{"key":"BFnrendo201049_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0006-291X(91)91325-7","volume":"179","author":"CX Moore","year":"1991","unstructured":"Moore, C. X. & Cooper, G. J. Co-secretion of amylin and insulin from cultured islet beta cells: modulation by nutrient secretogogues, islet hormones and hypoglycemic agents. Biochem. Biophys. Res. Commun. 179, 1\u20139 (1991).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"Suppl. 3","key":"BFnrendo201049_CR26","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","volume":"53","author":"O Schmitz","year":"2004","unstructured":"Schmitz, O., Brock, B. & Rungby, J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3), S233\u2013S238 (2004).","journal-title":"Diabetes"},{"key":"BFnrendo201049_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1042\/BST0320865","volume":"32","author":"DL Hay","year":"2004","unstructured":"Hay, D. L., Christopoulos, G., Christopoulos, A. & Sexton, P. M. Amylin receptors: molecular composition and pharmacology. Biochem. Soc. Trans. 32, 865\u2013867 (2004).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrendo201049_CR28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0026-895X(25)13212-4","volume":"44","author":"K Beaumont","year":"1993","unstructured":"Beaumont, K., Kenney, M. A., Young, A. A. & Rink, T. J. High affinity amylin binding sites in rat brain. Mol. Pharmacol. 44, 493\u2013497 (1993).","journal-title":"Mol. Pharmacol."},{"key":"BFnrendo201049_CR29","doi-asserted-by":"publisher","first-page":"R114","DOI":"10.1152\/ajpregu.00333.2003","volume":"286","author":"T Riediger","year":"2004","unstructured":"Riediger, T., Zuend, D., Becskei, C. & Lutz, T. A. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R114\u2013R122 (2004).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrendo201049_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0167-0115(97)01034-3","volume":"71","author":"NE Rowland","year":"1997","unstructured":"Rowland, N. E., Crews, E. C. & Gentry, R. M. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul. Pept. 71, 171\u2013174 (1997).","journal-title":"Regul. Pept."},{"key":"BFnrendo201049_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/archneurol.2008.581","volume":"66","author":"JD Roth","year":"2009","unstructured":"Roth, J. D., Maier, H., Chen. S. & Roland, B. L. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch. Neurol. 66, 306\u2013310 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrendo201049_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0196-9781(97)00292-1","volume":"19","author":"TA Lutz","year":"1998","unstructured":"Lutz, T. A. et al. Lesion of the area postrema\/nucleus of the solitary tract (AP\/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19, 309\u2013317 (1998).","journal-title":"Peptides"},{"key":"BFnrendo201049_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","volume":"25","author":"TA Lutz","year":"2001","unstructured":"Lutz, T. A., Mollet, A., Rushing, P. A., Riediger, T. & Scharrer, E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema\/nucleus of the solitary tract (AP\/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord. 25, 1005\u20131011 (2001).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"BFnrendo201049_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","volume":"137","author":"BR Gedulin","year":"2006","unstructured":"Gedulin, B. R., Jodka, C. M., Herrmann, K. & Young, A. A. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul. Pept. 137, 121\u2013127 (2006).","journal-title":"Regul. Pept."},{"key":"BFnrendo201049_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/014572179902500310","volume":"25","author":"D Kruger","year":"1999","unstructured":"Kruger, D., Gatcomb, P. M. & Owen, S. K. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 25, 389\u2013397 (1999).","journal-title":"Diabetes Educ."},{"key":"BFnrendo201049_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","volume":"37","author":"AA Young","year":"1996","unstructured":"Young, A. A. et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev. Res. 37, 231\u2013248 (1996).","journal-title":"Drug Dev. Res."},{"key":"BFnrendo201049_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/j.1552-4604.1996.tb04147.x","volume":"36","author":"WA Colburn","year":"1996","unstructured":"Colburn, W. A., Gottlieb, A. B., Koda, J. &, Kolterman, O. G. Pharmacokinetics and pharmacodynamics of AC137 (25, 28, 29 tripro amylin, human) after intravenous bolus and infusion doses in patients with insulin dependent diabetes. J. Clin. Pharmacol. 36, 13\u201324 (1996).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrendo201049_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/oby.2007.626","volume":"15","author":"I Chapman","year":"2007","unstructured":"Chapman, I. et al. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity 15, 1179\u20131186 (2007).","journal-title":"Obesity"},{"key":"BFnrendo201049_CR39","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","volume":"48","author":"I Chapman","year":"2005","unstructured":"Chapman, I. et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 48, 838\u2013848 (2005).","journal-title":"Diabetologia"},{"key":"BFnrendo201049_CR40","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","volume":"293","author":"SR Smith","year":"2007","unstructured":"Smith, S. R. et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am. J. Physiol. Endocrinol. Metab. 293, E620\u2013E627 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrendo201049_CR41","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1210\/jc.2006-2003","volume":"92","author":"L Aronne","year":"2007","unstructured":"Aronne, L. et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J. Clin. Endocrinol. Metab. 92, 2977\u20132983 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201049_CR42","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/dc08-0029","volume":"31","author":"SR Smith","year":"2008","unstructured":"Smith, S. R. et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31, 1816\u20131823 (2008).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s001250050949","volume":"41","author":"MF Kong","year":"1998","unstructured":"Kong, M. F. et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41, 577\u2013583 (1998).","journal-title":"Diabetologia"},{"key":"BFnrendo201049_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s001250050646","volume":"40","author":"MF Kong","year":"1997","unstructured":"Kong, M. F. et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40, 82\u201388 (1997).","journal-title":"Diabetologia"},{"key":"BFnrendo201049_CR45","first-page":"235A","volume":"45","author":"C Jodka","year":"1996","unstructured":"Jodka, C., Green, D., Young, A. & Gedulin, B. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve [abstract]. Diabetes 45, 235A (1996).","journal-title":"Diabetes"},{"key":"BFnrendo201049_CR46","doi-asserted-by":"publisher","first-page":"G946","DOI":"10.1152\/ajpgi.2000.278.6.G946","volume":"278","author":"M Samsom","year":"2000","unstructured":"Samsom, M. et al. Pramlintide, an amylin analog, selectively delays gastric emptying: a potential role of vagal inhibition. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G946\u2013G951 (2000).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"BFnrendo201049_CR47","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/meta.2002.32022","volume":"51","author":"MS Fineman","year":"2002","unstructured":"Fineman, M. S. et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51, 636\u2013641 (2002).","journal-title":"Metabolism"},{"key":"BFnrendo201049_CR48","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1055\/s-2002-34790","volume":"34","author":"M Fineman","year":"2002","unstructured":"Fineman, M., Weyer, C., Maggs, D. G., Strobel, S. & Kolterman, O. G. The human analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes. Horm. Metab. Res. 34, 504\u2013508 (2002).","journal-title":"Horm. Metab. Res."},{"key":"BFnrendo201049_CR49","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","volume":"54","author":"RA Heptulla","year":"2005","unstructured":"Heptulla, R. A., Rodriguez, L. M., Bomgaars, L. & Haymond, M. W. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 54, 1100\u20131107 (2005).","journal-title":"Diabetes"},{"key":"BFnrendo201049_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1172\/JCI108649","volume":"59","author":"JE Liljenquist","year":"1977","unstructured":"Liljenquist, J. E. et al. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J. Clin. Invest. 59, 369\u2013374 (1977).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo201049_CR51","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","volume":"26","author":"C Weyer","year":"2003","unstructured":"Weyer, C. et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 26, 3074\u20133079 (2003).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diacare.26.1.1","volume":"26","author":"C Levetan","year":"2003","unstructured":"Levetan, C. et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26, 1\u20138 (2003).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR53","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/diacare.28.3.632","volume":"28","author":"A Ceriello","year":"2005","unstructured":"Ceriello, A. et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28, 632\u2013637 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR54","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clinthera.2007.04.005","volume":"29","author":"D Singh-Franco","year":"2007","unstructured":"Singh-Franco, D., Robles, G. & Gazze, D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther. 29, 535\u2013562 (2007).","journal-title":"Clin. Ther."},{"key":"BFnrendo201049_CR55","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2337\/diacare.25.4.724","volume":"25","author":"F Whitehouse","year":"2002","unstructured":"Whitehouse, F. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25, 724\u2013730 (2002).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR56","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner, R. E. et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. 21, 1204\u20131212 (2004).","journal-title":"Diabet. Med."},{"key":"BFnrendo201049_CR57","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2337\/diacare.26.3.784","volume":"26","author":"PA Hollander","year":"2003","unstructured":"Hollander, P. A. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26, 784\u2013790 (2003).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/15209150252924094","volume":"4","author":"RE Ratner","year":"2002","unstructured":"Ratner, R. E. et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol. Ther. 4, 51\u201361 (2002).","journal-title":"Diabetes Technol. Ther."},{"key":"BFnrendo201049_CR59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2337\/dc06-1026","volume":"30","author":"DG Marrero","year":"2007","unstructured":"Marrero, D. G. et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 30, 210\u2013216 (2007).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR60","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/VHRM.S1978","volume":"4","author":"BJ Hoogwerf","year":"2008","unstructured":"Hoogwerf, B. J., Doshi, K. B. & Diab, D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc. Health Risk Manag. 4, 355\u2013362 (2008).","journal-title":"Vasc. Health Risk Manag."},{"key":"BFnrendo201049_CR61","doi-asserted-by":"crossref","unstructured":"FDA. Medication guide SYMLIN\u00ae (pramlintide acetate) injection NDA 21\u2013332 FDA [online] , (2005).","DOI":"10.3833\/pdr.v2005i60.663"},{"key":"BFnrendo201049_CR62","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2337\/dc06-0042","volume":"29","author":"S Edelman","year":"2006","unstructured":"Edelman, S. et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29, 2189\u20132195 (2006).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jpeds.2009.03.012","volume":"155","author":"HP Chase","year":"2009","unstructured":"Chase, H. P., Lutz, K., Pencek, R., Zhang, B. & Porter, L. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J. Pediatr. 155, 369\u2013373 (2009).","journal-title":"J. Pediatr."},{"key":"BFnrendo201049_CR64","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1210\/jc.2008-2580","volume":"94","author":"RA Heptulla","year":"2009","unstructured":"Heptulla, R. A., Rodriguez, L. M., Mason, K. J. & Haymond, M. W. Twenty-four-hour simultaneous subcutaneous basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J. Clin. Endocrinol. Metab. 94, 1608\u20131611 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201049_CR65","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jpeds.2009.04.065","volume":"155","author":"I Fennoy","year":"2009","unstructured":"Fennoy, I. Pramlintide in pediatric type 1 diabetes. J. Pediatr. 155, 308\u2013309 (2009).","journal-title":"J. Pediatr."},{"key":"BFnrendo201049_CR66","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0889-8529(05)70266-8","volume":"26","author":"HE Lebovitz","year":"1997","unstructured":"Lebovitz, H. E. Alpha-glucosidase inhibitors. Endocrinol. Metab. Clin. North Am. 26, 539\u2013551 (1997).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"BFnrendo201049_CR67","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1464-5491.1993.tb00149.x","volume":"10","author":"RB Tattersall","year":"1993","unstructured":"Tattersall, R. B. Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes. Diabet. Med. 10, 688\u2013693 (1993).","journal-title":"Diabet. Med."},{"key":"BFnrendo201049_CR68","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1475-2840-6-20","volume":"6","author":"M Hanefeld","year":"2007","unstructured":"Hanefeld, M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc. Diabetol. 6, 20 (2007).","journal-title":"Cardiovasc. Diabetol."},{"key":"BFnrendo201049_CR69","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2337\/diacare.20.3.248","volume":"20","author":"P Hollander","year":"1997","unstructured":"Hollander, P., Pi-Sunyer, X. & Coniff, R. F. Acarbose in the treatment of type 1 diabetes. Diabetes Care 20, 248\u2013253 (1997).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR70","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-2007-1012287","volume":"18","author":"G Dimitriadis","year":"1986","unstructured":"Dimitriadis, G., Karaiskos, C. & Raptis, S. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm. Metab. Res. 18, 253\u2013255 (1986).","journal-title":"Horm. Metab. Res."},{"key":"BFnrendo201049_CR71","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1464-5491.1999.00047.x","volume":"16","author":"G Riccardi","year":"1999","unstructured":"Riccardi, G. et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet. Med. 16, 228\u2013232 (1999).","journal-title":"Diabet. Med."},{"key":"BFnrendo201049_CR72","first-page":"235","volume-title":"Therapy for Diabetes Mellitus and Related Disorders","author":"CJ Bailey","year":"2009","unstructured":"Bailey, C. J. in Therapy for Diabetes Mellitus and Related Disorders 5th edn Ch. 21 (ed. Lebovitz, H. E.) 235\u2013253 (American Diabetes Association, Alexandria, USA, 2009)."},{"key":"BFnrendo201049_CR73","doi-asserted-by":"crossref","unstructured":"Vella, S. et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia doi:10.1007\/s00125-009-1636-9.","DOI":"10.1007\/s00125-009-1636-9"},{"key":"BFnrendo201049_CR74","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2337\/diacare.25.12.2153","volume":"25","author":"L Meyer","year":"2002","unstructured":"Meyer, L. et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 25, 2133\u20132158 (2002).","journal-title":"Diabetes Care"},{"key":"BFnrendo201049_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1742-7843.2009.00380.x","volume":"105","author":"IB Jacobsen","year":"2009","unstructured":"Jacobsen, I. B., Henriksen, J. E. & Beck-Nielsen, H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin. Pharmacol. Toxicol. 105, 145\u2013149 (2009).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"BFnrendo201049_CR76","doi-asserted-by":"publisher","first-page":"e3363","DOI":"10.1371\/journal.pone.0003363","volume":"3","author":"SS Lund","year":"2008","unstructured":"Lund, S. S. et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS ONE 3, e3363 (2008).","journal-title":"PLoS ONE"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.49","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:34:28Z","timestamp":1740018868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2010.49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFnrendo201049"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2010.49","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}